Physicians' Academy for Cardiovascular Education

Patients with heterozygous familial hypercholesterolemia benefit from PCSK9-antibody

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo with heterozygous familial hypercholesterolemia

Literature - Kastelein JJP, Hovingh GH, Langslet G et al. - J Clin Lipidol, 2017, DOI:

Main results


In four studies with HeFH patients, alirocumab resulted in significant LDL-C-lowering in most patients who were receiving the maximally tolerated dose of a statin, with or without other lipid-lowering therapies.


Show references

Find this article online at J Clin Lipidol

Share this page with your colleagues and friends: